Gossamer Bio's drug for pulmonary arterial hypertension failed to reach the primary objective in the third phase of the clinical trial. The study failed in the last phase. Still, Gossamer Bio plans to seek FDA approval. The drug is intended for the treatment of pulmonary arterial hypertension. The primary endpoint was not met.